@megamutts, I think it all depends on PK/PD and what feladilimab does is likely very different to what Efti does in that regard and including drug (combo) interactions. So, again, this may well shift/tip the attention (including Merck's of course) to Efti. As I underestand Efti's wide *ranging* safety and efficacy profile so far (including combo with Keytruda) will be a clear advantage going into phase III, or II/III.
Ann: Immutep Investor Update, page-48
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
40.0¢ |
Change
-0.005(1.23%) |
Mkt cap ! $581.0M | |||
| Open | High | Low | Value | Volume |
| 41.0¢ | 41.5¢ | 39.5¢ | $1.576M | 3.906M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2506 | 39.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 40.0¢ | 8079 | 1 |
View Market Depth
| Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
| IMM (ASX) Chart |